Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 DSM, Crucell Sign Licensing Deal with Taiwanese DCB | Contract Pharma

What are you searching for?

Sign in
Breaking News

DSM, Crucell Sign Licensing Deal with Taiwanese DCB

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

DSM Biologics and Crucell N.V. have signed a non-exclusive PER.C6 research licensing deal with Taipei, Taiwan-headquartered Development Center for Biotechnology (DCB). DCB will use the human cell line for its in-house production of undisclosed recombinant proteins. This PER.C6 license is Crucell’s second license in Taiwan for recombinant protein production. The PER.C6 technology platform has been developed for the large-scale manufacture of biopharmaceutical products including vaccines.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters